@article{07fb0fbe9528409fb921e846bfd3fabd,
title = "Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis",
abstract = "Emerging evidence underlines the importance of micro(mi)RNAs in the pathogenesis of multiple sclerosis (MS). Free-circulating miRNAs were investigated in serum from MS patients compared to controls. Statistically significant decreased levels of miR-15b, miR-23a and miR-223 were observed in MS patients (p < 0.05). Results were validated and replicated in two further independent MS populations. A direct correlation between miRNA levels and the EDSS score was determined in PPMS (p < 0.007). The generalized trend toward miRNA down-regulation could result in over-expression of target genes involved in disease pathogenesis. Circulating miRNA profiling could thus represent a new avenue to identify easily detectable disease biomarkers.",
keywords = "Multiple sclerosis, biomarkers, demyelination, microRNA, serum",
author = "Chiara Fenoglio and Elisa Ridolfi and Claudia Cantoni and {De Riz}, Milena and Rossana Bonsi and Maria Serpente and Chiara Villa and Pietroboni, {Anna M.} and Naismith, {Robert T.} and Enrique Alvarez and Parks, {Becky J.} and Nereo Bresolin and Cross, {Anne H.} and Piccio, {Laura M.} and Daniela Galimberti and Elio Scarpini",
note = "Funding Information: This work was supported by grants from the Italian Ministry of Health (Giovani Ricercatori 2007, D.lgs 502/92). This publication was made possible by Grant Number UL1 RR024992 from the National Center for Research Resources (NCRR) and National Center for nslational Sciences (NCATS), components of the US National Institutes of Health (NIH). L.P. is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society (NMSS) (JF 2144A2/1) and is funded by the Fondazione Italiana Sclerosi Multipla (2009/R/33). E.A. is Sylvia Lawry Fellow from the National MS Society and Predoctoral Training Program at Washington University UL1RR024995. Funding Information: Dr. Naismith has received consulting fees and speaking honoraria from Acorda Therapeutics, Bayer Healthcare, Biogen Idec, EMD Serono, Genzyme Corporation and Teva Neurosciences. Research funding is through the NIH (K23NS052430-01A1), NMSS and Acorda Therapeutics. ",
year = "2013",
month = dec,
doi = "10.1177/1352458513485654",
language = "English",
volume = "19",
pages = "1938--1942",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
number = "14",
}